糖皮质激素受体靶向脂质体递送wnt/β-catenin通路抑制剂选择性诱导结直肠肿瘤有效消退。

IF 5.5 3区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Pritam Das, Tithi Bhattacharyya, Aasia Ansari, Anjaneyulu Eanti, Yogesh Chandra, Rajkumar Banerjee
{"title":"糖皮质激素受体靶向脂质体递送wnt/β-catenin通路抑制剂选择性诱导结直肠肿瘤有效消退。","authors":"Pritam Das, Tithi Bhattacharyya, Aasia Ansari, Anjaneyulu Eanti, Yogesh Chandra, Rajkumar Banerjee","doi":"10.1007/s13346-025-01952-3","DOIUrl":null,"url":null,"abstract":"<p><p>Wnt/β-catenin signaling pathway is a highly conserved developmental pathway. This pathway is also involved in colorectal cancer and thus its selective targeting to cancer cells, albeit the risk involved, can serve as a promising therapeutic approach. Glucocorticoid receptor (GR) is a nuclear hormone receptor present in both cancer and non-cancer cells. Previously, we showed that cancer cell-associated GR, without eliciting any effect in normal cells, could be targeted for selective drug-sensitization in cancer cells. Based on this unique feature, we intended to sensitize the wnt/β-catenin pathway by co-formulating a GR-targeted cationic liposomal formulation carrying dexamethasone, a synthetic GR-ligand, and a wnt/β-catenin pathway inhibitor, FH535, to form D1XFH formulation. The nanometric and positively charged D1XFH formulation selectively kills colorectal cancer cells at much lower FH535 concentration than free drug or drug-associated GR-non-targeted liposome, while exhibiting unique nuclear uptake, increased ROS generation, apoptosis and G2-M phase cell cycle arrest in cancer cells. Further, in vivo data shows enhanced tumor-specific localization of this formulation, significant tumor growth inhibition and increased mice survivability, signifying its efficacy and biocompatibility in mouse colon subcutaneous and orthotopic tumor models. Protein expression analysis reveals enhanced reversal of epithelial-to-mesenchymal transition (EMT) and inhibition of various downstream proteins of wnt/β-catenin pathway. Additionally, analysis of tumor lysate from D1XFH-treated group shows an increased Th1/Th2 ratio, indicating favorable, anti-tumor immune response. The formulation exhibits no sub-chronic toxicity against healthy mice. In overall, our data strongly suggest that the GR-targeted FH535 liposomal delivery can safely target the highly sensitive wnt/β-catenin pathway for effective treatment of colorectal tumor.</p>","PeriodicalId":11357,"journal":{"name":"Drug Delivery and Translational Research","volume":" ","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Glucocorticoid receptor-targeted liposomal delivery of wnt/β-catenin pathway inhibitor selectively induces efficient colorectal tumor regression.\",\"authors\":\"Pritam Das, Tithi Bhattacharyya, Aasia Ansari, Anjaneyulu Eanti, Yogesh Chandra, Rajkumar Banerjee\",\"doi\":\"10.1007/s13346-025-01952-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Wnt/β-catenin signaling pathway is a highly conserved developmental pathway. This pathway is also involved in colorectal cancer and thus its selective targeting to cancer cells, albeit the risk involved, can serve as a promising therapeutic approach. Glucocorticoid receptor (GR) is a nuclear hormone receptor present in both cancer and non-cancer cells. Previously, we showed that cancer cell-associated GR, without eliciting any effect in normal cells, could be targeted for selective drug-sensitization in cancer cells. Based on this unique feature, we intended to sensitize the wnt/β-catenin pathway by co-formulating a GR-targeted cationic liposomal formulation carrying dexamethasone, a synthetic GR-ligand, and a wnt/β-catenin pathway inhibitor, FH535, to form D1XFH formulation. The nanometric and positively charged D1XFH formulation selectively kills colorectal cancer cells at much lower FH535 concentration than free drug or drug-associated GR-non-targeted liposome, while exhibiting unique nuclear uptake, increased ROS generation, apoptosis and G2-M phase cell cycle arrest in cancer cells. Further, in vivo data shows enhanced tumor-specific localization of this formulation, significant tumor growth inhibition and increased mice survivability, signifying its efficacy and biocompatibility in mouse colon subcutaneous and orthotopic tumor models. Protein expression analysis reveals enhanced reversal of epithelial-to-mesenchymal transition (EMT) and inhibition of various downstream proteins of wnt/β-catenin pathway. Additionally, analysis of tumor lysate from D1XFH-treated group shows an increased Th1/Th2 ratio, indicating favorable, anti-tumor immune response. The formulation exhibits no sub-chronic toxicity against healthy mice. In overall, our data strongly suggest that the GR-targeted FH535 liposomal delivery can safely target the highly sensitive wnt/β-catenin pathway for effective treatment of colorectal tumor.</p>\",\"PeriodicalId\":11357,\"journal\":{\"name\":\"Drug Delivery and Translational Research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2025-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Delivery and Translational Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13346-025-01952-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery and Translational Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13346-025-01952-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

Wnt/β-catenin信号通路是一个高度保守的发育通路。这一途径也与结直肠癌有关,因此它选择性靶向癌细胞,尽管存在风险,但可以作为一种有希望的治疗方法。糖皮质激素受体(GR)是一种存在于癌细胞和非癌细胞中的核激素受体。之前,我们发现癌细胞相关的GR在正常细胞中不引起任何作用,但可以作为癌细胞选择性药物致敏的靶点。基于这一独特的特性,我们打算通过共同配制gr靶向阳离子脂质体制剂,携带地塞米松,合成gr配体和wnt/β-catenin途径抑制剂FH535,形成D1XFH制剂,使wnt/β-catenin通路增敏。与游离药物或药物相关的gr -非靶向脂质体相比,纳米级带正电荷的D1XFH制剂在FH535浓度低得多的情况下选择性杀死结直肠癌细胞,同时在癌细胞中表现出独特的核摄取、ROS生成增加、细胞凋亡和G2-M期细胞周期阻滞。此外,体内数据显示,该制剂可增强肿瘤特异性定位,显著抑制肿瘤生长,提高小鼠存活率,表明其在小鼠结肠皮下和原位肿瘤模型中的有效性和生物相容性。蛋白表达分析显示,上皮-间质转化(EMT)逆转增强,wnt/β-catenin通路的多种下游蛋白受到抑制。此外,d1xfh处理组的肿瘤裂解物分析显示Th1/Th2比率增加,表明有利的抗肿瘤免疫反应。该制剂对健康小鼠无亚慢性毒性。总的来说,我们的数据强烈表明,gr靶向FH535脂质体递送可以安全靶向高度敏感的wnt/β-catenin通路,有效治疗结直肠癌。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Glucocorticoid receptor-targeted liposomal delivery of wnt/β-catenin pathway inhibitor selectively induces efficient colorectal tumor regression.

Wnt/β-catenin signaling pathway is a highly conserved developmental pathway. This pathway is also involved in colorectal cancer and thus its selective targeting to cancer cells, albeit the risk involved, can serve as a promising therapeutic approach. Glucocorticoid receptor (GR) is a nuclear hormone receptor present in both cancer and non-cancer cells. Previously, we showed that cancer cell-associated GR, without eliciting any effect in normal cells, could be targeted for selective drug-sensitization in cancer cells. Based on this unique feature, we intended to sensitize the wnt/β-catenin pathway by co-formulating a GR-targeted cationic liposomal formulation carrying dexamethasone, a synthetic GR-ligand, and a wnt/β-catenin pathway inhibitor, FH535, to form D1XFH formulation. The nanometric and positively charged D1XFH formulation selectively kills colorectal cancer cells at much lower FH535 concentration than free drug or drug-associated GR-non-targeted liposome, while exhibiting unique nuclear uptake, increased ROS generation, apoptosis and G2-M phase cell cycle arrest in cancer cells. Further, in vivo data shows enhanced tumor-specific localization of this formulation, significant tumor growth inhibition and increased mice survivability, signifying its efficacy and biocompatibility in mouse colon subcutaneous and orthotopic tumor models. Protein expression analysis reveals enhanced reversal of epithelial-to-mesenchymal transition (EMT) and inhibition of various downstream proteins of wnt/β-catenin pathway. Additionally, analysis of tumor lysate from D1XFH-treated group shows an increased Th1/Th2 ratio, indicating favorable, anti-tumor immune response. The formulation exhibits no sub-chronic toxicity against healthy mice. In overall, our data strongly suggest that the GR-targeted FH535 liposomal delivery can safely target the highly sensitive wnt/β-catenin pathway for effective treatment of colorectal tumor.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Drug Delivery and Translational Research
Drug Delivery and Translational Research MEDICINE, RESEARCH & EXPERIMENTALPHARMACOL-PHARMACOLOGY & PHARMACY
CiteScore
11.70
自引率
1.90%
发文量
160
期刊介绍: The journal provides a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. Rationally developed, effective delivery systems can potentially affect clinical outcome in different disease conditions. Research focused on the following areas of translational drug delivery research will be considered for publication in the journal. Designing and developing novel drug delivery systems, with a focus on their application to disease conditions; Preclinical and clinical data related to drug delivery systems; Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes Short-term and long-term biocompatibility of drug delivery systems, host response; Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering; Image-guided drug therapy, Nanomedicine; Devices for drug delivery and drug/device combination products. In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of the Controlled Release Society.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信